With key catalysts due over the next seven months, including in Q2 with preliminary glioblastoma (GBM) data, Curasight’s major inflection point is fast approaching. We expect a positive outcome from the study. We believe management will be able to deliver the GBM data in good time to put the company in a position to strengthen its balance sheet. We reiterate our fair equity value range of DKK 14-36 per share.

Link to the analysis